Wolfgang M. Kuebler, Martin R. Stämpfli, Oliver Eickelberg, Nelly Frossard, Bruno Crestani, Martin Kolb, Tania Maes, Pierre-Simon Bellaye, Bernard Maitre, Gisli Jenkins, Ulrich A. Maus, Eric S. White, Wei Shi, Aurelie Fabre, Luca Richeldi, Martin Witzenrath, Antoine Magnan, Guy Joos, Philippe Bonniaud, Petra Reinhold, Stefan Uhlig, Heinz Fehrenbach, Christophe Guignabert, Andreas Guenther, Mark D. Inman, Juanita H. J. Vernooy, Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Pneumologie Soins Intensifs, Appareillage Respiratoire [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Université Bourgogne Franche-Comté [COMUE] (UBFC), St Vincent's University Hospital, Laboratoire d'Innovation Thérapeutique (LIT), Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Institut de Chimie du CNRS (INC), LabEx Medalis, Université de Strasbourg (UNISTRA), INSERM, UMR_S 999, Laboratoire d’Excellence (LabEx) en Recherche sur le Médicament et l’Innovation Thérapeutique (LERMIT), Université Paris Sud (Paris 11), St Joseph's Hopital and the Department of Medicine (FIRESTONE INSTITUTE FOR RESPIRATORY HEALTH), Mc Master University, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Ghent University Hospital, The Saban Research Institute of Children’s Hospital Los Angeles [Los Angeles, CA, USA], University of Southern California (USC), Plateforme d'imagerie préclinique [Centre Georges-François Leclerc] (CGFL), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Institut du thorax, Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), McMaster University [Hamilton, Ontario], Pulmonologie, and RS: FHML non-thematic output
Experimental models are critical for the understanding of lung health and disease and are indispensable for drug development. However, the pathogenetic and clinical relevance of the models is often unclear. Further, the use of animals in biomedical research is controversial from an ethical perspective.The objective of this task force was to issue a statement with research recommendations about lung disease models by facilitating in-depth discussions between respiratory scientists, and to provide an overview of the literature on the available models. Focus was put on their specific benefits and limitations. This will result in more efficient use of resources and greater reduction in the numbers of animals employed, thereby enhancing the ethical standards and translational capacity of experimental research.The task force statement addresses general issues of experimental research (ethics, species, sex, age,ex vivoandin vitromodels, gene editing). The statement also includes research recommendations on modelling asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, lung infections, acute lung injury and pulmonary hypertension.The task force stressed the importance of using multiple models to strengthen validity of results, the need to increase the availability of human tissues and the importance of standard operating procedures and data quality.